Business
Sun BioPharma, Inc. Appoints Jennifer K. Simpson, Ph.D., as President and CEO
Sun BioPharma, Inc. Appoints Jennifer K. Simpson, Ph.D., as President and CEO.
About this update from Panbela Therapeutics, Inc.
[{"type":"text","content":"\n MINNEAPOLIS, July 16, 2020 (GLOBE NEWSWIRE) --  Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today announced the appointment of Jennifer K. Simpson, Ph.D., as President and Chief Executive Officer. Dr. Simpson was also appointed to the Company’s Board of Directors. Dr. Simpson brings more than two decades of public company executive and fundraising experience in oncology drug development and commercialization to Sun BioPharma, most recently having served as CEO of Delcath Systems, Inc. Sun BioPharma co-founder Michael T. Cullen, M.D, MBA, will continue to serve as Executive Chairman of Sun BioPharma’s Board of Directors. “Recent interim clinical trial results demonstrated an overall tumor response rate of 62% for Sun BioPharma’s compound SBP-101, a significant improvement versus standard therapy for patients with pancreatic cancer,” said Dr. Simpson. “I’m excited to join the team and help the Company realize the full potential of SBP-101 for patients in an area of unmet medical need having this orphan disease.” “Dr. Simpson’s career spans oncology drug development from early clinical stage through commercialization, and her executive experience and oncology product clinical and commercial expertise will expedite the access of cancer patients to this potential advance in treatment,” said Dr. Cullen. “I am delighted to be working with her.” Dr. Simpson has more than 25 years of experience across a variety of executive, business operations, marketing and clinical development roles in the biopharmaceutical industry. Prior to her appointment as CEO of Delcath Systems, Dr. Simpson served as its Executive Vice President, and Global Head of Business Operations. Previous to joining Delcath, Dr. Simpson held a variety of positions of increasing responsibility at ImClone Systems, Inc. and Johnson & Johnson Ortho-Biotech. Earlier in her career, she spent over a decade as a hematology/oncology nurse practitioner and educator. Dr. Simpson holds a Ph.D. in Epidemiology from the University of Pittsburgh, an M.S. in Nursing from the University of Rochester, and a B.S. in Nursing from the State University of New York at Buffalo. Sun BioPh...